Original Article

Experimental study of radioimmunotherapy versus chemotherapy for colorectal cancer†

  1. G. M. de Jong1,*,
  2. R. P. Bleichrodt1,
  3. A. Eek2,
  4. W. J. G. Oyen2,
  5. O. C. Boerman2,
  6. T. Hendriks1

Article first published online: 15 DEC 2010

DOI: 10.1002/bjs.7361

Issue

British Journal of Surgery

British Journal of Surgery

Volume 98, Issue 3, pages 436–441, March 2011

Additional Information

How to Cite

de Jong, G. M., Bleichrodt, R. P., Eek, A., Oyen, W. J. G., Boerman, O. C. and Hendriks, T. (2011), Experimental study of radioimmunotherapy versus chemotherapy for colorectal cancer. British Journal of Surgery, 98: 436–441. doi: 10.1002/bjs.7361

Author Information

  1. 1

    Department of Surgery, Division of Oncology and Abdominal Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  2. 2

    Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

*490 Department of Surgery, Division of Oncology and Abdominal Surgery, Radboud University Nijmegen Medical Centre, PO Box 9101, 6525 GA Nijmegen, The Netherlands

  1. †

    Presented to a meeting of the Society of Nuclear Medicine, Salt Lake City, Utah, USA, June 2010, and a meeting of the European Society of Surgical Oncology, Bordeaux, France, September 2010; and published in abstract form as J Nucl Med 2010; 51(Suppl 2): 59 and Eur J Surg Oncol 2010; (in press)

Publication History

  1. Issue published online: 20 JAN 2011
  2. Article first published online: 15 DEC 2010
  3. Manuscript Accepted: 12 OCT 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (138K)

A promising targetted therapy

Abstract

Background:

Radioimmunotherapy (RIT) has been shown to reduce the incidence of local recurrence of colorectal cancer in an experimental model. The aim of the present study was to investigate the survival benefit of RIT compared with chemotherapy.

Methods:

An anastomosis was constructed in male Wag/Rij rats after intraluminal injection of CC531 tumour cells. The therapeutic efficacy of 177Lu-labelled MG1 (single intravenous dose of 300 MBq/kg, n = 20) was compared with that of 5-fluorouracil-based chemotherapy (6 weekly cycles administered intraperitoneally, n = 20) and no treatment (n = 20). The primary endpoint was survival. Toxicity was monitored by bodyweight measurement.

Results:

Both chemotherapy and RIT affected bodyweight, but the weight of animals in the RIT group remained significantly higher than in the chemotherapy group (median slope of bodyweight plot 0·48 versus 0·30 g/day; P < 0·001). Kaplan–Meier analysis showed that overall survival in the RIT and chemotherapy groups was significantly better than that in the control group (50 and 46 per cent versus 25 per cent respectively after 170 days; P = 0·024 and P = 0·029). Survival after treatment with RIT did not differ from that after chemotherapy (P = 0·911).

Conclusion:

RIT is as effective as chemotherapy in experimental colorectal cancer. Copyright © 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

View Full Article (HTML) Get PDF (138K)